Abstract:Background Acute lung injury/acute respiratory distress syndrome presents with not only local inflammation, but also pulmonary coagulopathy which is characterized by an alveolar procoagulant response, anticoagulant inhibition, fibrinolytic supression and fibrin deposition. We thus had hypothesized that if aerosolized unfractionated heparin was inhaled into alveolar spaces, it could block the procoagulant tendency, lessen depletion of coagulation factors, and even influence the inflammatory response. We also assessed the effects of different administration regimens of heparin. Methods Male Wistar rats were given inhaled heparin starting 30 minutes before (prophylactic heparin) or 2 hours after (therapeutic heparin) intravenous lipopolysaccharide (LPS) was administered at 6-hour intervals; control groups received inhaled normal saline with or without being exposed to LPS. Thrombin-antithrombin complexes, activated protein C, tissue type and urokinase type plasminogen activators (t-PA/u-PA), plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-a, interleukin-6 in bronchoalveolar lavage, and lung tissue nnyeloperoxidase activity, and histology score were measured at three time-points. PAI-1/(t-PA + u-PA) was calculated based on the before-mentioned parameters. Statistical analysis was made using one-way analysis of variance (ANOVA) with post hoc test or Student's t test in the case of heterogeneity of variance. Results An alveolar procoagulant reaction, depressed fibrinolysis, and inflammatory response occurred in endotoxemia-induced lung injury. Local prophylactic application of heparin attenuated coagulation and early inflammation, promoted fibrinolysis, and reduced the histology score. Therapeutic application of heparin had similar, but weaker effects. Conclusions Intrapulmonary application of unfractionated heparin by inhalation might inhibit alveolar procoagulant reaction and the early inflammatory response, promote fibrinolysis, and alleviate pulmonary pathology in endotoxemia-induced lung injury rats. Administration of heparin before LPS challenge was more efficacious.

Inhaled heparin: Past, present, and future

Not Just Anticoagulation—New and Old Applications of Heparin

Pharmacological and clinical application of heparin progress: An essential drug for modern medicine

Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy

Research Progress on Antiviral Activity of Heparin

Research Progress of Low Molecular Weight Heparin

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease

Advances in the Discovery of Novel Inhaled PI3K Inhibitors for the Treatment of Asthma

Pharmacology of Heparin and Related Drugs

Advanced Nanocarriers Based on Heparin and Its Derivatives for Cancer Management.

Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review

The Preventive and Therapeutic Effects of Acute and Severe Inflammatory Disorders with Heparin and Heparinoid

Bioengineered heparin: Advances in production technology

Non-Anticoagulant Activities of Low Molecular Weight Heparins—A Review

Inhaled drug delivery: Past, present, and future

Another new application of heparin in COVID-19: more than anticoagulation and antiviral

Comprehensive Landscape of Heparin Therapy for COVID-19

Safety and Pharmacokinetics of Intranasally Administered Heparin

Non-anticoagulant heparin derivatives for COVID-19 treatment

Inhaled unfractionated heparin improves abnormalities of alveolar coagulation, fibrinolysis and inflammation in endotoxemia-induced lung injury rats.

Heparin Mimetics As Potential Intervention for COVID-19 and Their Bio-Manufacturing